BeiGene
BGNE
$313.99
Share price
0.49%
Change (1 day)
34.83%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
EPS for BeiGene (BGNE)
EPS in 2023 (TTM): -$27.43
According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$28.29. In 2022 the company made an earnings per share (EPS) of -$32.93 a decrease over its 2021 EPS that were of -$25.86.
EPS history for BeiGene from 2015 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | -$27.43 | -16.7% |
| 2022 | -$32.93 | 27.35% |
| 2021 | -$25.86 | -19.96% |
| 2020 | -$32.30 | 20.81% |
| 2019 | -$26.74 | 31.52% |
| 2018 | -$20.33 | 417.57% |
| 2017 | -$3.93 | -37.16% |
| 2016 | -$6.25 | 158.95% |
| 2015 | -$2.41 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 | -$1.70 | -93.99% | 🇺🇸 USA |
 | -$0.46 | -98.38% | 🇺🇸 USA |